Nomograms on salvage radiotherapy

Nomograms on salvage radiotherapy

Cleveland Clinic

2 months
2 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Shauna Campbell, MD of Cleveland Clinic shares three nomograms that were presented on salvage radiotherapy.

_____

The integration of prostate-specific antigen (PSA) kinetics into a nomogram widely used to predict outcomes of salvage therapy offers physicians and patients a more nuanced, longer-term look at prostate cancer-specific outcomes.

In 2007, a multi-institutional cohort led by Cleveland Clinic’s Glickman Urological and Kidney Institute developed a nomogram to predict prostate cancer-specific and all-cause mortality at six years after salvage radiotherapy (SRT).

Almost a decade later, a study led by Cleveland Clinic Cancer Center radiation oncologist Rahul D. Tendulkar, MD, updated the nomogram with evidence that early initiation of SRT following radical prostatectomy (RP) reduced biochemical failure (BF) and distant metastases (DM).

The researchers’ most recent update to the nomogram was presented at the 2019 annual meeting of the American Society for Radiation Oncology (ASTRO).

“One critique of our previous update was the lack of PSA kinetics among the predictive factors,” says Shauna Campbell, DO, chief resident, radiation oncology, Cleveland Clinic. “This version of the nomogram adds initial postoperative PSA level and PSA doubling time [PSADT] to the picture.”

Read the rest here: https://consultqd.clevelandclinic.org/postprostatectomy-prostate-specific-antigen-kinetics-associated-with-recurrence-after-salvage-radiation/

Up Next Autoplay
Analysis of Patients with Prior Gastrectomy Treated with LONSURF® (trifluridine and tipiracil) Published in JAMA Oncology
Analysis of Patients with Prior Gastrectomy Treated with LONSURF® (trifluridine and tipiracil) Published in JAMA Oncology
Category: Pancreatic Cancer
12 Views
Cancer-News 1 month
Pancreatic Cancer Discovery Reveals How the Aggressive Cancer Fuels Its Growth
Pancreatic Cancer Discovery Reveals How the Aggressive Cancer Fuels Its Growth
Category: Pancreatic Cancer
12 Views
Cancer-News 1 month
Soricimed Announces Initiation of Patient Dosing for First Cohort in Investigator-Initiated Phase 1b Clinical trial of SOR-C13
Soricimed Announces Initiation of Patient Dosing for First Cohort in Investigator-Initiated Phase 1b Clinical trial of SOR-C13
Category: Pancreatic Cancer
10 Views
Cancer-News 1 month
How does it differ from previously published nomograms?
How does it differ from previously published nomograms?
Category: Pancreatic Cancer
1 Views
Cleveland Clinic 2 months
Moleculin Announces its Sponsored Research at MD Anderson Cancer Center Has Resulted in the Filing of Patent Protection for New Discovery
Moleculin Announces its Sponsored Research at MD Anderson Cancer Center Has Resulted in the Filing of Patent Protection for New Discovery
Category: Pancreatic Cancer
7 Views
Cancer-News 2 months
Unanswered Questions in the POLO Trial
Unanswered Questions in the POLO Trial
Category: Pancreatic Cancer
6 Views
moasc 2 months
The POLO Study
The POLO Study
Category: Pancreatic Cancer
2 Views
moasc 2 months
SOR-C13 is the leading drug in a phase 1b trial in pancreatic cancer
SOR-C13 is the leading drug in a phase 1b trial in pancreatic cancer
Category: Pancreatic Cancer
124 Views
Cancer-News 2 months
SOR-C13 possibly disrupts how TRPV6 functions
SOR-C13 possibly disrupts how TRPV6 functions
Category: Pancreatic Cancer
77 Views
Cancer-News 2 months